GlassScriptPhysician profile
Kathryn J Shaw
NPI 1316944457
$572.86
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $162 · 2021: $16.58 · 2023: $351 · 2024: $43.53.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $394.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $394.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ge Healthcare | $141.57 | 2019 | |
| Mirum Pharmaceuticals, INC. | $140.89 | 2023 | Livmarli |
| Myriad Women'S Health, INC. | $66.30 | 2023 | Myrisk |
| Baxter Healthcare | $49.05 | 2023 | Tisseel |
| Dexcom, INC. | $24.92 | 2024 | Dexcom G6 Transmitter |
| Coopersurgical, INC. | $24.27 | 2023 | Paragard T 380a |
| Bayer Healthcare Pharmaceuticals INC. | $22.69 | 2023 | |
| Amag Pharmaceuticals, INC. | $20.55 | 2019 | |
| Sage Therapeutics, LLC | $18.61 | 2024 | |
| Hologic Sales and Service, LLC | $16.96 | 2023 | Myosure Tissue Removal Device |
| Biogen, INC. | $16.58 | 2021 | |
| Becton, Dickinson and Company | $15.80 | 2023 | Bd Onclarity |
| Sumitomo Pharma America, INC. | $14.67 | 2023 | Myfembree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathryn Shaw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.